Claims for Patent: 12,304,813

Summary for Patent: 12,304,813

Title:	Sodium thiosulfate-containing pharmaceutical compositions
Abstract:	Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.
Inventor(s):	Craig Sherman, Catherine Marie Smith, Kevin Robert Wirtz, Erich Schulze
Assignee:	Hope Medical Enterprises Inc
Application Number:	US18/947,430
Patent Claims:	1. A unit-dosage form comprising pharmaceutical grade sodium thiosulfate which contains no greater than about 10 ppm of non-purgeable organic carbon, contains no greater than about 0.05 ppm of mercury, contains no greater than about 2 ppm of aluminum, contains no greater than about 0.003% by weight of selenium, contains no less than about 98% by weight and no greater than about 102% by weight of sodium thiosulfate on an anhydrous basis measured by ion chromatography, has a heavy metal content of no greater than about 10 ppm, contains no greater than about 200 ppm of chloride, contains no greater than about 0.001% by weight of sulfide, contains no greater than about 0.002% by weight of iron, contains no greater than about 0.01% by weight of calcium, contains no greater than about 0.005% by weight of potassium, contains no greater than about 0.1% by weight of sulfite, contains no greater than about 0.5% by weight of sulfate, contains no greater than about 3 ppm of arsenic, contains no greater than about 0.001% by weight of lead, has total aerobic count of microbial load of no greater than about 100 CFU/g, has total yeast and mold count of no greater than about 20 CFU/g, contains no greater than about 0.02 EU/mg of bacterial endotoxins, contains no greater than about 0.002% by weight of nitrogen compounds, contains no greater than about 0.005% by weight of insoluble matter, contains no greater than 0.01% by weight of residual anti-caking agent, and contains no greater than ICH Q3C (R3) limits of organic volatile impurities, wherein a 10% aqueous solution of the sodium thiosulfate at 25° C. is colorless and has a pH between about 6.0 and about 8.0. 2. The unit-dosage form of claim 1, wherein the pharmaceutical grade sodium thiosulfate contains no greater than about 8 ppm of non-purgeable organic carbon. 3. The unit-dosage form of claim 1, wherein the pharmaceutical grade sodium thiosulfate is anhydrous. 4. The unit-dosage form of claim 1, which is packaged in a vial. 5. A unit-dosage form comprising a pharmaceutical composition, wherein the pharmaceutical composition comprises pharmaceutical grade sodium thiosulfate in an aqueous pharmaceutically acceptable carrier, wherein the sodium thiosulfate used to prepare the pharmaceutical composition contains no greater than about 10 ppm of non-purgeable organic carbon, contains no greater than about 0.05 ppm of mercury, contains no greater than about 2 ppm of aluminum, contains no greater than about 0.003% by weight of selenium, contains no less than about 98% by weight and no greater than about 102% by weight of sodium thiosulfate on an anhydrous basis measured by ion chromatography, has a heavy metal content of no greater than about 10 ppm, contains no greater than about 200 ppm of chloride, contains no greater than about 0.001% by weight of sulfide, contains no greater than about 0.002% by weight of iron, contains no greater than about 0.01% by weight of calcium, contains no greater than about 0.005% by weight of potassium, contains no greater than about 0.1% by weight of sulfite, contains no greater than about 0.5% by weight of sulfate, contains no greater than about 3 ppm of arsenic, contains no greater than about 0.001% by weight of lead, has total aerobic count of microbial load of no greater than about 100 CFU/g, has total yeast and mold count of no greater than about 20 CFU/g, contains no greater than about 0.02 EU/mg of bacterial endotoxins, contains no greater than about 0.002% by weight of nitrogen compounds, contains no greater than about 0.005% by weight of insoluble matter, contains no greater than 0.01% by weight of residual anti-caking agent, and contains no greater than ICH Q3C (R3) limits of organic volatile impurities. 6. The unit-dosage form of claim 5, wherein the aqueous pharmaceutically acceptable carrier is sterile water for injection. 7. The unit-dosage form of claim 6, wherein the pharmaceutical grade sodium thiosulfate contains no greater than about 8 ppm of non-purgeable organic carbon. 8. The unit-dosage form of claim 6, wherein the pharmaceutical composition is formulated for intravenous administration. 9. The unit-dosage form of claim 6, wherein the pharmaceutical composition is formulated for infusion administration. 10. The unit-dosage form of claim 6, wherein the pharmaceutical composition further comprises an isotonic agent and one or more pH adjusting agents. 11. The unit-dosage form of claim 10, wherein the pharmaceutical composition is sterile and suitable for intravenous administration, wherein the isotonic agent is potassium chloride, present at about 4.40 mg/mL and the pH adjusting agents are boric acid, present at about 2.80 mg/mL, and sodium hydroxide. 12. The unit-dosage form of claim 11, wherein the pharmaceutical grade sodium thiosulfate is present at a concentration of about 250.0 mg/mL of sodium thiosulfate pentahydrate as measured on an anhydrous basis. 13. The unit-dosage form of claim 11, wherein the pharmaceutical composition comprises about 140 mg boric acid and about 220 mg potassium chloride. 14. The unit-dosage form of claim 13, wherein the pharmaceutical composition further comprises pharmaceutical grade sodium thiosulfate present at a concentration of about 12.5 grams of sodium thiosulfate pentahydrate as measured on an anhydrous basis. 15. The unit-dosage form of claim 6, wherein the pharmaceutical grade sodium thiosulfate used to make the pharmaceutical composition is anhydrous.